USO 24301

A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer(JZP598-208)

Disease Types: Breast Cancer Research

Eligibility Requirements:

Has Stage II or III histologically confirmed invasive breast carcinoma.
Has histologically confirmed HER2-positive breast cancer
Has a known hormone receptor (HR) status of the primary tumor
Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is HER2-positive, and the treating physician has determined the participant should be treated as HER2-positive.
Agrees to undergo a mastectomy or breast conserving surgery (BCS) after neoadjuvant therapy.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function
Has an LVEF ≥ 50% as determined by either ECHO or MUGA obtained within 4 weeks prior to first dose of study intervention.
Adequate contraceptive precautions

For more details on this trial CLICK HERE .

Available at:

• Chesapeake
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg
• Newport News (Port Warwick III)